Medical Device Recall in China: Grading, Process and Local Execution by Overseas Holders

1. Key takeaways

Recall is one of the five statutory duties set for the holder by Article 20, paragraph 1 of the Medical Device Supervision and Administration Regulation (State Council Order No. 739); it is item (4), and the provision is framed around active recall, with the holder as first responsible party.

• Grading follows defect severity and possible harm to health. The number of grades, their criteria and the corresponding time limits are not within the provisions verified here; the rules in force apply (practical estimate).
• Entrusted manufacture does not transfer recall responsibility: Article 41 of the Production Measures (SAMR Order No. 53) addresses recall and trustee assistance, while Article 34 of the Regulation allocates responsibility.
• An overseas holder lands the duty through its China agent: Article 20, paragraph 2 and Article 14, paragraph 2 of the Measures give obligation abroad, execution in China.
• The boundary with change registration and filing must be settled first: recall addresses a defect in a marketed product, change registration a substantive change affecting safety or effectiveness, filing any other change (Article 79, within 30 days).
• Recall records support renewal: with a five-year certificate and a six-month deadline (Article 22, paragraph 1), a poorly executed recall surfaces there.

2. Legal basis

Administrative regulation. Medical Device Supervision and Administration Regulation (State Council Order No. 739), promulgated 9 February 2021, effective 1 June 2021.

• Articles 5, 13: risk management, whole-process control, scientific supervision, social co-governance; Class I filed, Class II and III registered, with lifecycle liability.
• Article 20, paragraph 1: five duties, item (4) covering traceability and recall; paragraph 2: the designated Chinese legal entity assists in these duties.
• Article 21: substantive change requires change registration. Article 22, paragraph 1: validity five years, renewal six months before expiry.
• Article 34: in-house or entrusted manufacture, and the principle for allocating responsibility between holder and trustee.

Departmental rules. Measures for the Administration of Medical Device Registration and Filing (SAMR Order No. 47), promulgated 26 August 2021, effective 1 October 2021.

• Article 14, paragraph 2: the overseas applicant or filer designates a Chinese legal entity as agent, to assist in the Article 20 duties and in giving effect to liability. Articles 15, 24: quality system, risk management.
• Article 79: substantive change requires change registration; other changes filed within 30 days; holder and agent names and addresses fall within filing. Article 107: fine of RMB 10,000 to 30,000 for failure to file.

Production rules. Measures for the Supervision and Administration of Medical Device Production (SAMR Order No. 53), promulgated 10 March 2022, effective 1 May 2022. Article 4: production is classified, Class II and III requiring a licence, Class I a filing. Article 41: recall requirements and the trustee’s assistance duty (wording outside the verification scope here; the text in force governs).

Normative document. Registration QMS Inspection Guideline (Notice No. 50 of 2022), 29 September 2022, effective on issue, repealing Notice No. 19 of 2020.

Practical estimate. The number of grades, their criteria, notification and implementation time limits, and the effectiveness evaluation deadline are not within the verified provisions. The process below is industry practice with no regulatory force; on launching a recall, follow the provincial and accepting-department requirements in force.

3. Expert insights

The keyword is active, and entrustment does not move responsibility. Article 20, paragraph 1, item (4) places recall among the holder’s duties, emphasising voluntary implementation. Article 34 permits entrusting a qualified manufacturer, but the principle is that the holder bears primary responsibility and the trustee bears the responsibility agreed with it. Entrustment changes how production is organised, not who owns the recall duty.

The third column executes and the fourth is liable; the two must not be merged. GRZAN requires this as a separate clause, not a general undertaking to cooperate on quality.

Grading sets the intensity of action, so assessment comes before grading. Grading is not the starting point but an intermediate output; the starting point is the risk assessment.

Grading first and assessing afterwards is the commonest sequencing error: notification scope and disposal then mismatch the real risk, producing either under-recall or an unnecessary supply shock.

The trustee’s assistance boundary. Article 41 addresses recall and the trustee’s assistance (the wording is outside the verification scope here; the text in force governs). Four actions at least must be covered.

Written only as cooperate, none of the four is operable: the trustee controls scheduling, retention samples and record formats, so without agreed deadlines the holder’s decision stalls at information gathering.

Domestic landing for the overseas holder. Article 20, paragraph 2 and Article 14, paragraph 2 form the landing chain; an imported recall needs one more domestic layer.

The second link is the most underestimated: a Chinese template drafted only after the recall begins pushes publication back appreciably (practical estimate). GRZAN keeps templates and flow confirmation forms by product line as standing documents.

Where recall, change registration and filing divide.

One quality event often touches several routes at once: the marketed batch is recalled, the design change goes to change registration, and the label update goes to filing. Filing is what gets dropped, yet Article 107 sets a fine of RMB 10,000 to 30,000.

4. Practical recommendations

• Put recall decision rights into the entrustment agreement, holder as decision-maker, trustee as support under Article 41, with an itemised list.
• Prepare grading templates in advance, fixing the record forms for the five steps from identification to effectiveness evaluation.
• Set deadlines and formats for trustee information on batch, distribution, inventory and retention samples.
• Authorise interim domestic action in advance, with the scope of authority and a ratification mechanism to shorten decision transfer.
• Keep Chinese notification templates by product line, one each for facilities and distributors.
• Run the three routes in parallel with a filing checkpoint, so the filing is not lost inside the recall timetable.
• Review recall records twelve months before renewal, given the five-year certificate and the six-month deadline (practical estimate).

5. Verification checklist

• □ Item (4) of the five duties assigned a recall decision-maker
• □ Procedure fixes the five steps from identification to evaluation
• □ Grading built on the risk assessment, not set before it
• □ Entrustment agreement assigns decision rights to the holder and support to the trustee (Article 41)
• □ Deadlines and formats for trustee information agreed
• □ Interim domestic authority signed for the agent
• □ Chinese recall templates and flow confirmation forms kept by product line
• □ Filing checkpoint set where the three routes run in parallel
• □ Filing-scope changes completed within 30 days (Article 79)
• □ Recall records numbered and archived across the whole chain
• □ Renewal window six months before expiry in the project calendar

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Chinese market. Our team manages adverse event monitoring and recall filings with NMPA, maintains UDI compliance, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com